Analyst Ratings for Gilead Sciences (GILD) [Buys]

Overall Rating: BUY Rating Trend: Down

Avg. $ Target: $64.47 (+27.4%)

Date	Firm	Type	Rating (Past)	PT (Past)	Start $	End $	% Chg.	Details
6/13/2013	Argus	Upgrade	Buy (Hold)	N/A (N/A)	51.17	50.60	-1.11%	Details
2/19/2013	Credit Suisse	Upgrade	Outperform (Neutral)	N/A (N/A)	41.60	50.60	21.63%	Details
11/9/2012	Guggenheim	New Coverage	Buy (N/A)	87.00 (N/A)	64.85	50.60	-21.97%	Details
10/8/2012	Lazard Capital	Upgrade	Buy (Neutral)	N/A (N/A)	69.43	50.60	-27.12%	Details
10/1/2012	Bernstein	Upgrade	Outperform (Market Perform)	N/A (N/A)	66.33	50.60	-23.71%	Details
8/2/2012	Barclays » Updated 8/28/2012	Upgrade	Overweight (Equalweight)	65.00 (N/A)	53.63	50.60	-5.65%	Details
7/17/2012	Maxim Group » Updated 4/22/2013	New Coverage	Buy (N/A)	97.00 (48.00)	51.94	50.60	-2.58%	Details
3/15/2012	Stifel Nicolaus	New Coverage	Buy (N/A)	57.00 (N/A)	46.66	50.60	8.44%	Details
2/10/2012	Morgan Stanley	New Coverage	Overweight (N/A)	65.00 (N/A)	53.73	50.60	-5.83%	Details
11/22/2011	BMO Capital	Upgrade	Outperform (N/A)	49.00 (N/A)	36.26	50.60	39.55%	Details
11/21/2011	Citi » Updated 3/18/2013	Upgrade	Buy (N/A)	60.00 (46.00)	35.08	50.60	44.24%	Details
8/9/2011	Brean Capital » Updated 8/28/2012	New Coverage	Buy (N/A)	60.00 (N/A)	36.82	50.60	37.43%	Details
6/29/2011	Piper Jaffray	Upgrade	Overweight (N/A)	N/A (N/A)	40.95	50.60	23.57%	Details
1/6/2011	Williams Capital	New Coverage	Outperform (N/A)	N/A (N/A)	37.53	50.60	34.83%	Details
12/10/2010	Wells Fargo » Updated 3/5/2013	New Coverage	Outperform (N/A)	N/A (N/A)	36.99	50.60	36.79%	Details

Like GILD Ratings? Also take a look at IDIX, BMY, VRTX, GSK